ROCKVILLE, Md. — November 5, 2025 — Leads & Copy —
MaxCyte, Inc. (NASDAQ: MXCT) announced preliminary results for the third quarter ended September 30, 2025, and reiterated its 2025 revenue guidance. Core business revenue was $6.4 million, with $0.4 million from the Strategic Platform License SPL Program. Total revenue reached $6.8 million, with a gross margin of $5.2 million (77%). The non-GAAP adjusted gross margin was 81%. MaxCyte added Moonlight Bio as a new SPL client in October, bringing the total SPL agreements to 32. Total cash, cash equivalents, and investments were $158.0 million as of September 30, 2025.
The company rescheduled its third quarter 2025 financial results release and conference call to November 12, 2025, to review technical accounting matters related to impairment testing of goodwill and long-lived assets. This testing considers favorable announcements from SPL partners and does not affect prior quarters’ results.
MaxCyte will host a conference call on November 12, 2025, at 4:30 p.m. Eastern Time, and management will present at the Stifel Healthcare Conference on November 11, 2025, and the Stephens Investment Conference on November 19, 2025.
Investor Relations Contact:
David Deuchler, CFA
Gilmartin Group
+1 415-937-5400
ir@maxcyte.com
Media Contact:
Kristen White
Oak Street Communications
kristen@oakstreetcommunications.com
415.608.6060
Source: MaxCyte
